![Thomas Taapken](data:image/svg+xml,<svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" fill="%231b1b1b" class="bi bi-person-fill" viewBox="0 0 16 16"><path d="M3 14s-1 0-1-1 1-4 6-4 6 3 6 4-1 1-1 1zm5-6a3 3 0 1 0 0-6 3 3 0 0 0 0 6"/></svg>)
Thomas Taapken
Directeur Financier/CFO chez
INFLARX N.V.
Fortune : 6 300 $ au 30/09/2026
Profil
Thomas Taapken is currently Chief Executive Officer at Bluehaven Therapeutics AG, Chairman at ImCyse SA since 2019, Director at SciBase AB since 2017, Chief Financial Officer at elbion NV, and Chief Financial Officer at InflaRx NV since 2020.
Former positions include CEO, CFO & Investor Relations Contact at Biotie Therapies Oy from 2008 to 2011; Independent Director at Memo Therapeutics AG from 2021 to 2023; Partner at Burrill LLC from 1998 to 2002; Chief Executive & Financial Officer at MediGene AG from 2017 to 2018; Chief Executive & Financial Officer at Epigenomics AG from 2011 to 2016; Chief Financial Officer at elbion AG in 2007; Director at Immunic AG; Independent Director at SciBase Holding AB; Partner at DVC Deutsche Venture Capital; and Principal at Sanofi-Aventis Deutschland GmbH.
Education includes a doctorate from the Technical University of Berlin conferred in 1994.
Détentions connues dans des sociétés publiques
| Société | Date | Nombre d'actions | Valorisation | Date de valorisation |
|---|---|---|---|---|
INFLARX N.V. 0 % | 18/03/2026 | 3 500 ( 0 % ) | 6 300 $ | 30/09/2026 |
Postes actifs de Thomas Taapken
| Sociétés | Poste | Début |
|---|---|---|
| INFLARX N.V. | Directeur Financier/CFO | 01/10/2020 |
elbion NV
 elbion NV Pharmaceuticals: MajorHealth Technology Discovers and develops therapeutics for neurological diseases | Directeur Financier/CFO | - |
ImCyse SA
 ImCyse SA BiotechnologyHealth Technology Engages in the development of curative therapies in the field of immune and allergic pathologies | Président | 01/01/2019 |
Bluehaven Therapeutics AG | Directeur Général | - |
Scibase AB | Directeur/Membre du Conseil | 01/01/2017 |
Anciens postes connus de Thomas Taapken
| Sociétés | Poste | Fin |
|---|---|---|
Memo Therapeutics AG
 Memo Therapeutics AG Pharmaceuticals: MajorHealth Technology Operates as a biotech company translating unique human immune responses into superior medicines through the development of best-in-class antibodies to treat viral infections and cancer | Directeur/Membre du Conseil | 01/12/2023 |
| MEDIGENE AG | Directeur Général | 31/08/2018 |
| EPIGENOMICS AG | Directeur Général | 30/06/2016 |
| BIOTIE THERAPIES CORP | Directeur Général | 01/04/2011 |
| ░░░░░░ ░░ | ░░░░░░░░░ ░░░░░░░░░░░░░ | ░░░░░░░░░░ |
Formation de Thomas Taapken
Expériences
Fonctions occupées
Actives
Inactives
Sociétés cotées
Entreprise privées
Relations
73
Relations au 1er degré
16
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Entreprise privées | 16 |
|---|---|
elbion NV
elbion NV Pharmaceuticals: MajorHealth Technology Discovers and develops therapeutics for neurological diseases | Health Technology |
Burrill LLC
 Burrill LLC Investment ManagersFinance Burrill invests in companies located in the United States. The firm focuses on a broad range of sectors. It participates in buyout and early-stage transactions. | Finance |
MediGene AG
 MediGene AG BiotechnologyHealth Technology Engages in the clinical research and development of novel drugs against cancer & autoimmune diseases with focus on personalized immunotherapies | Health Technology |
Biotie Therapies Oy
 Biotie Therapies Oy Pharmaceuticals: MajorHealth Technology Engages in research, development and commercialization of pharmaceutical products | Health Technology |
Epigenomics AG
 Epigenomics AG Medical SpecialtiesHealth Technology Engages in the development and commercialization of in vitro diagnostic tests for cancer | Health Technology |
DVC Deutsche Venture Capital
 DVC Deutsche Venture Capital Investment ManagersFinance DVC is a venture capital investment manager focused on European high-growth, early-stage companies with global expansion potential. The firm invests in sectors including life sciences, information technology, telecommunication, semiconductor and industrial technologies. In the field of life sciences, DVC invests specifically in the development of therapeutic products, diagnostics, medical devices and biotechnology platforms. Their technology investments target businesses whose activity pertains to 1) the management of information, applications and infrastructure, 2) communication applications and platforms as well as network infrastructure, and 3) technologies related to optics, automation, sensors, electronics, semiconductors and materials. DVC aims to leverage their access to Deutsche Bank's international network and lead their portfolio companies from technological leadership to international market success. Investment criteria include distinctive technology with adequate IP protection and addressing a clearly identified market, an experienced management team and leadership potential in high-growth markets internationally. The firm is generally the lead investor in German-speaking countries, and co-leads in other European countries and the US. They aim to keep their portfolio balanced across their target sectors and across development stages, with a majority of early-stage investments complemented with expansion-phase investments with short-term exit potential. DVC actively assists their portfolio companies with financial issues, key hires and marketing strategy without interfering in operational management. | Finance |
SciBase Holding AB
 SciBase Holding AB Medical SpecialtiesHealth Technology Develops point of care device for the detection of malignant melanoma | Health Technology |
elbion AG
 elbion AG Miscellaneous Commercial ServicesCommercial Services Discovers and develops new small molecule drugs | Commercial Services |
Technical University of Berlin
 Technical University of Berlin Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Sanofi-Aventis Deutschland GmbH
 Sanofi-Aventis Deutschland GmbH Pharmaceuticals: MajorHealth Technology Manufactures and markets pharmaceutical products & provides research and development services | Health Technology |
ImCyse SA
ImCyse SA BiotechnologyHealth Technology Engages in the development of curative therapies in the field of immune and allergic pathologies | Health Technology |
Scibase AB | |
Memo Therapeutics AG
Memo Therapeutics AG Pharmaceuticals: MajorHealth Technology Operates as a biotech company translating unique human immune responses into superior medicines through the development of best-in-class antibodies to treat viral infections and cancer | Health Technology |
Immunic AG
 Immunic AG Pharmaceuticals: MajorHealth Technology Develops pharmaceuticals in the immunology space | Health Technology |
InflaRx NV
 InflaRx NV BiotechnologyHealth Technology Develops biopharmaceutical products | Health Technology |
Bluehaven Therapeutics AG |
